title: Increased A3AR-dependent vasoconstriction in diabetic mice is promoted by myeloperoxidase.
abstract: Vascular dysfunction importantly contributes to mortality and morbidity in various cardiac and metabolic diseases. Among endogenous molecules regulating vascular tone is adenosine, with the adenosine A3 receptor (A3AR) exerting cardioprotective properties in ischemia and reperfusion. However, overexpression of A3AR is suggested to result in vascular dysfunction and inflammation. The leukocyte enzyme myeloperoxidase (MPO) is an important modulator of vascular function with nitric oxide-consuming and proinflammatory properties. Increased MPO plasma levels are observed in patients with cardiovascular disorders like heart failure, acute coronary syndromes, and arrhythmias. Given that vascular dysfunction and inflammation are also hallmarks of diabetes, the role of MPO in adenosine-dependent vasomotor function was investigated in a murine model of diabetes mellitus. Wild-type (WT) and MPO-deficient (Mpo) mice were treated with Streptozotocin (STZ), which induced an increase of MPO plasma levels in WT mice and led to enhanced aortic superoxide generation as assessed by dihydroethidium staining in STZ-treated WT mice as compared with controls. The vasoconstriction of aortic segments in response to the A3AR agonist Cl-IB-MECA (2-Chloro-N6-(3-iodobenzyl)-N-methyl-5-carbamoyladenosine) as determined by isometric force measurements was augmented in diabetic WT as compared with diabetic Mpo mice. Moreover, A3AR protein expression was enhanced in STZ-treated mice but was attenuated by MPO deficiency. The current data reveal an MPO-mediated increase of vascular A3AR expression under diabetic conditions, which leads to enhanced vasoconstriction in response to A3AR agonists and discloses an additional mechanism of MPO-mediated vascular dysfunction.
authors.affiliation: *Department of Biosciences, Jamia Millia Islamia, New Delhi, India; †University Medical Center Hamburg-Eppendorf, Hamburg, Germany; and ‡Heart Centre and Department of Internal Medicine, Cardiovascular Research Centre Cologne, University of Cologne, Cologne, Germany.
authors.forename: Shamama
authors.initials: S
authors.lastname: Nishat
authors.forename: Anna
authors.initials: A
authors.lastname: Klinke
authors.forename: Stephan
authors.initials: S
authors.lastname: Baldus
authors.forename: Luqman Ahmad
authors.initials: LA
authors.lastname: Khan
authors.forename: Seemi Farhat
authors.initials: SF
authors.lastname: Basir
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D058909:Adenosine A3 Receptor Agonists / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009195:Peroxidase / Q000235:genetics / Q000378:metabolism*; D043684:Receptor, Adenosine A3 / Q000187:drug effects / Q000378:metabolism*; D013311:Streptozocin; D013481:Superoxides / Q000378:metabolism; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology*
chemical_list: D058909:Adenosine A3 Receptor Agonists; D043684:Receptor, Adenosine A3; D013481:Superoxides; D013311:Streptozocin; D009195:Peroxidase; D000241:Adenosine; C090034:2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide